Immuneering Corp. Class A (IMRX)

Immuneering Corp. experienced a significant stock price increase, with a 250.96% increase between November 2024 and November 2025. The company reported exceptional overall survival and progression-free survival data from its Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer patients. Immuneering closed an underwritten public offering of approximately 18.9 million shares, raising about $175 million, complemented by a $25 million private investment from Sanofi. The announcement of the public stock offering led to a downturn in the stock value due to dilution concerns among investors. Leerink Partners initiated coverage of Immuneering with an "Outperform" recommendation. Immuneering reported its Q3 2025 financial results on November 12, 2025, posting an EPS of -$0.38, meeting analysts' expectations. A newly issued U.S. composition of matter patent for atebimetinib is expected to provide exclusivity into 2042.

Immuneering Corp. does not experience traditional demand seasonality for products and services. Its demand is primarily driven by the progress and success of its clinical trials, regulatory milestones, and the ability to secure funding for its research and development activities. The company's financial performance and stock valuation are more influenced by clinical data readouts, regulatory approvals, and financing rounds rather than seasonal consumer demand for a marketed product.

Immuneering Corp. is a clinical-stage oncology company focused on developing novel medicines for cancer patients, operating in the biotechnology industry with a focus on major pharmaceuticals. The company advances oncology and neuroscience product candidates through its translational bioinformatics platform, aiming to improve patient outcomes by developing treatments for solid tumors caused by mutations in the MAPK and mTOR pathways. Its lead product candidate is IMM-1-104 (atebimetinib), an oral MEK inhibitor in Phase 2a clinical trials for various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer. The company's development pipeline also includes IMM-6-415, which is in Phase 1/2a clinical trials for solid tumors, and early-stage neuroscience programs like IMM-ALL-01 and IMM-ALL-03 for Alzheimer's Disease.

Immuneering Corporation is headquartered in Cambridge, Massachusetts, United States.

Immuneering's brand reputation has been positively impacted by promising clinical trial results for IMM-1-104 in pancreatic cancer. The company received an "Outperform" recommendation from Leerink Partners in October 2025, reflecting positive sentiment from financial analysts. Sanofi's $25 million private investment signals confidence from a major pharmaceutical industry player. The granting of a U.S. composition of matter patent for atebimetinib enhances the company's intellectual property and long-term prospects. The public stock offering in September 2025 led to a temporary stock price decline due to dilution concerns, but it did not negatively impact the company's scientific or clinical reputation.

Immuneering Corp. has a diverse ownership structure, with individual investors holding around 54% of the company's shares. Insiders own approximately 10.03% to 14% of shares, with CEO Benjamin J. Zeskind being a major individual shareholder. Major institutional owners include Fmr Llc, Sanofi, Vanguard Group Inc, Price T Rowe Associates Inc /md/, ExodusPoint Capital Management, LP, Logos Global Management LP, Citadel Advisors Llc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, BlackRock, Inc., Blue Owl Capital Holdings LP, HBM Healthcare Investments (Cayman) Ltd., and Cormorant Asset Management LP.